Management of overt hepatic encephalopathy.
Hepatic encephalopathy (HE) is a potentially reversible state of impaired cognitive function or altered consciousness in patients with liver disease or portosystemic shunting. Overt HE is a particularly pressing problem. Given the many targets of treatment and lack of a clear singular cause of overt HE, there is no consensus on a single best treatment. Over the past several years, high-quality studies have been conducted on the various pharmacologic therapies for HE and, as more data emerge, hopefully HE will become a much more easily treated complication of decompensated liver disease.
Department of Medicine, Cedars-Sinai Medical Center, 8635 West Third Street, Suite 1060, Los Angeles, CA 90048, USA. vandana.khungar@gmail.com
Vandana
V
Khungar
Fred
F
Poordad
D020909:Acarbose / Q000627:therapeutic use; D000641:Ammonia / Q000378:metabolism; D019468:Disease Management; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D006501:Hepatic Encephalopathy / Q000175:diagnosis* / Q000378:metabolism / Q000628:therapy*; D006801:Humans; D007792:Lactulose / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012294:Rifamycins / Q000627:therapeutic use; D000078262:Rifaximin
D005765:Gastrointestinal Agents; D012294:Rifamycins; D007792:Lactulose; D000641:Ammonia; D000078262:Rifaximin; D020909:Acarbose